Molecular therapy for TIIDM and obesity-associated metabolic deficits: N-Acetyl Serotonin increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 7/December/2017, 7.13 am

Natural product therapy for body weight control, energy homeostasis and TIIDM:  Huperzine A decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 7/December/2017, 6.18 am
December 7, 2017
Natural product-based therapy for Deafness: a therapeutic mix encompassing Venlafaxine, Cholecalciferol, Ajoene and DIM (VCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 7/December/2017, 8.33 am
December 7, 2017
Show all

Introduction: What they say

A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by bone-derived lipocalin 2.” This research paper was published, in the 8 March 2017 issue of the journal “Nature” [One of the best research journals in General Science with an I.F of 43 plus], by Dr. Stavroula Kousteni and Mosialou and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for TIIDM and obesity-associated metabolic deficits: N-Acetyl Serotonin increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene

price-quote


From significance of the study to public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) diabetic disease results in a number of health complications, including diabetic cardiomyopathy (DCM), diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy; (3) one third of people with diabetes suffer from diabetic kidney disease (DKD); and one third of them will develop kidney failure; (4) Obesity plays a central role in the development of TIIDM; (5) Diabetes is going to be one of the top 10 causes of death by 2030; (6) the life-long painful injection/drug treatment is required to treat DM; (7) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

Dr. Stavroula Kousteni’s research team has recently shown, using loss-and gain-of-function experiments, that Lipocalin 2 (LCN2): (1) induces insulin release; (2) improves glucose tolerance; and (3) augments insulin sensitivity. Further, they have shown that LCN2: (1) binds and activates the melanocortin 4 receptor (MC4R) in the neurons of the hypothalamus; (2) activates an MC4R-dependent appetite-suppressing pathway; (3) suppresses appetite and body weight gain; (4) levels are low in TIIDM patients and they are inversely correlated with body weight gain and blood A1c levels; and (5) levels are higher in patients with lower body weight gain and blood A1c levels, suggesting that increasing the expression of LCN2 may alleviate metabolic deficits in diabetic patients.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, a natural product based therapy for TIIDM and Obesity-associated disorders.

Figure 1. Mechanistic insights into how N-Acetyl Seratonin suppresses appetite and promotes insulin secretion

Figure 2. The chemical structure of N-Acetyl Seratonin. N-Acetyl Seratonin may function as an anti-diabetic agent.

N-Acetyl Serotonin, by increasing the expression of its target gene, it may increase the expression of LCN2. Thereby, it may: (1) induce insulin release; (2) increase expression of components of the Insulin-PI3K pathway; (3) promote glucose tolerance; (4) improve insulin sensitivity; (5) activate the MC4R-dependent appetite-suppressing pathway in hypothalamus; (6) suppress appetite; and weight gain; (7) improve metabolic deficits; and (8) promote glucose homeostasis (Fig.1). Thus, pharmacological formulations encompassing “N-Acetyl Serotonin or its analogues, either alone or in combination with other drugs,” may be used to treat TIIDM and Obesity-associated metabolic deficits/abnormalities.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does N-Acetyl Serotonin increase the expression of LCN2 to promote insulin secretion?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Molecular therapy for TIIDM and obesity-associated metabolic deficits: N-Acetyl Serotonin increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 7/December/2017, 7.14 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.